• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    1/24/23 5:27:10 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOXW alert in real time by email
    425 1 form425.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 23, 2023

     

    FOXWAYNE ENTERPRISES ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39891   85-3093926

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    1 Rockefeller Plaza, Suite 1039

    New York, New York 10020

    (Address of principal executive offices, including ZIP code)

     

    (917) 284-8938

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425 )
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant   FOXWU   The Nasdaq Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   FOXW   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share   FOXWW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On January 23, 2023, Foxwayne Enterprise Acquisition Corp. (the “Company”) determined to cancel its special meeting of stockholders that was originally scheduled for November 30, 2022 and postponed until January 18, 2023, and to withdraw from consideration by the stockholders of the Company the proposals set forth in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on December 22, 2022.

     

    In addition, on January 23, 2023, the Company also determined, that due to its inability to consummate an initial business combination within the time period required by its Second Amended and Restated Certificate of Incorporation, as amended (the “Charter”), the Company intends to dissolve and liquidate in accordance with the provisions of its the Charter and will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares that were issued in its initial public offering (the “Public Shares”), at a per-share redemption price of approximately $10.175.

     

    As of the close of business on January 27, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount.

     

    In order to provide for the disbursement of funds from the trust account, the Company will instruct the trustee of the trust account to take all necessary actions to liquidate the securities held in the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after January 27, 2023.

     

    The Company’s sponsor has agreed to waive its redemption rights with respect to its outstanding ordinary shares issued prior to the Company’s initial public offering.

     

    There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless.

     

    -2-

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: January 24, 2023 FoxWayne Enterprises Acquisition Corp.
         
      By: /s/ Robb Knie
      Name: Robb Knie
      Title: Chief Executive Officer

     

    -3-

     

    Get the next $FOXW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOXW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FOXW
    SEC Filings

    View All

    SEC Form 15-12G filed by FoxWayne Enterprises Acquisition Corp.

    15-12G - FoxWayne Enterprises Acquisition Corp. (0001829999) (Filer)

    2/6/23 5:17:14 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by FoxWayne Enterprises Acquisition Corp.

    25-NSE - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/27/23 4:38:29 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    425 - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/24/23 5:27:10 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

    NEW YORK, Nov. 29, 2022 /PRNewswire/ -- FoxWayne Enterprises Acquisition Corp. ("FoxWayne" or the "Company") (Nasdaq: "FOXW", "FOXWU", "FOXWW") announced today that its special meeting of stockholders (the "Special Meeting") originally scheduled for Wednesday, November 30, 2022, is being postponed to Tuesday December 13, 2022. At the Special Meeting, stockholders will be asked to vote on the following proposals: (1) a proposal to approve an amendment (the "Extension Amendment") to the Company's Second Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a business combination for three months, from January 22, 2023 (the "Original Terminati

    11/29/22 5:20:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Live Streaming Social Entertainment Platform Powering the Creator Economy, Clover Inc., to Merge with Special Purpose Acquisition Company, FoxWayne Enterprises Acquisition Corp., to Become Public Company

    New entity poised to accelerate the development of Clover's next generation platform for live streaming with a suite of new product introductions. Clover has a growing user base of over 9 million with almost 90% of users between 18-39 years old.  Clover is targeting a launch of VR ('Virtual Reality') Dating and VR Live Streaming in Q4 2023. NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Clover Inc. ("Clover" or the "Company"), a highly rated live streaming company focused on Gen Z and Millennial audiences and creators, and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW, FOXWW) ("FoxWayne"), a special purpose acquisition company ("SPAC"), today announced they have entered into a definitive bu

    9/20/22 8:08:00 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    DURHAM, N.C. and NEW YORK, March 4, 2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition Corp. (NASDAQ:FOXW) ("FoxWayne"), a publicly traded special purpose acquisition company ("SPAC"), announced today that they have mutually agreed to terminate their previously announced business combination agreement, effective immediately. In light of current unfavorable market conditions, Aerami and FoxWayne believe that

    3/4/22 4:30:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/13/24 7:35:39 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/12/24 11:00:29 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    3/10/23 4:03:05 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care